Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Neuro-Oncology, Journal Year: 2020, Volume and Issue: 22(8), P. 1073 - 1113

Published: April 20, 2020

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause morbidity mortality. In recent years there have been advances in understanding molecular pathogenesis biology these tumors, but this has not translated into significantly improved outcomes for patients. consensus review from Society Neuro-Oncology (SNO) European Association (EANO), current management isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. addition, novel therapies such as targeted therapies, agents targeting DNA damage response metabolism, immunotherapies, viral reviewed, well challenges future directions research.

Language: Английский

---

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Cancer Cell, Journal Year: 2020, Volume and Issue: 37(4), P. 471 - 484

Published: April 1, 2020

Language: Английский

---

Genomic Evolution of Breast Cancer Metastasis and Relapse

Cancer Cell, Journal Year: 2017, Volume and Issue: 32(2), P. 169 - 184.e7

Published: Aug. 1, 2017

Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with having dismal survival. We sequenced whole genomes or a panel 365 genes on 299 samples from 170 locally relapsed cancer. Several lines analysis indicate that clones seeding metastasis relapse disseminate late tumors, but continue to acquire mutations, mostly accessing the same mutational processes active tumor. Most distant metastases acquired driver mutations seen tumor, drawing wider repertoire than early drivers. These include number clinically actionable alterations inactivating SWI-SNF JAK2-STAT3 pathways.

Language: Английский

---

The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment

Cell, Journal Year: 2018, Volume and Issue: 174(6), P. 1347 - 1360

Published: Sept. 1, 2018

Language: Английский

---

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 19(1), P. 23 - 36

Published: Sept. 10, 2021

Language: Английский

---

Stem cell fate in cancer growth, progression and therapy resistance

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 18(11), P. 669 - 680

Published: Sept. 18, 2018

Language: Английский

---

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

Oncogene, Journal Year: 2018, Volume and Issue: 37(12), P. 1561 - 1575

Published: Jan. 8, 2018

Language: Английский

---

Circular ecDNA promotes accessible chromatin and high oncogene expression

Nature, Journal Year: 2019, Volume and Issue: 575(7784), P. 699 - 703

Published: Nov. 20, 2019

Language: Английский

---

Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers

Nature Genetics, Journal Year: 2020, Volume and Issue: 52(9), P. 891 - 897

Published: Aug. 17, 2020

Language: Английский

---

MYC Deregulation in Primary Human Cancers

Genes, Journal Year: 2017, Volume and Issue: 8(6), P. 151 - 151

Published: May 25, 2017

MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, is master regulator of many processes, including cell cycle entry, ribosome biogenesis, metabolism. In cancer, the activity transcriptional network frequently deregulated, contributing to initiation maintenance disease. Deregulation often leads constitutive overexpression MYC, which can be achieved through gross genetic abnormalities, copy number alterations, chromosomal translocations, increased enhancer activity, or aberrant signal transduction leading transcription mRNA protein stability. Herein, we summarize frequency modes deregulation describe both well-established more recent findings in variety cancer types. Notably, these studies have highlighted that with an appreciation for basic mechanisms deregulating new therapeutic vulnerabilities discovered potentially exploited inhibition this potent oncogene cancer.

Language: Английский

---